$426.67 Million in Sales Expected for Amedisys Inc (AMED) This Quarter

Analysts expect Amedisys Inc (NASDAQ:AMED) to report sales of $426.67 million for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Amedisys’ earnings. The lowest sales estimate is $420.77 million and the highest is $431.10 million. Amedisys reported sales of $404.24 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.5%. The business is expected to announce its next earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Amedisys will report full year sales of $1.66 billion for the current year, with estimates ranging from $1.64 billion to $1.66 billion. For the next fiscal year, analysts forecast that the firm will post sales of $1.77 billion, with estimates ranging from $1.74 billion to $1.79 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Amedisys.

Amedisys (NASDAQ:AMED) last released its earnings results on Monday, October 29th. The health services provider reported $0.95 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.18. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The company had revenue of $417.34 million during the quarter, compared to analysts’ expectations of $411.05 million. During the same quarter last year, the business earned $0.56 EPS. The business’s revenue was up 11.7% on a year-over-year basis.

Several analysts have recently commented on AMED shares. Royal Bank of Canada raised their target price on shares of Amedisys to $115.00 and gave the stock an “outperform” rating in a research note on Friday, August 3rd. Robert W. Baird raised their target price on shares of Amedisys from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Thursday, October 11th. Bank of America set a $139.00 target price on shares of Amedisys and gave the stock a “buy” rating in a research note on Tuesday, September 18th. BidaskClub cut shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 16th. Finally, Cantor Fitzgerald started coverage on shares of Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 target price for the company. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $105.50.

In other news, insider David L. Kemmerly sold 3,375 shares of the stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $117.44, for a total value of $396,360.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David B. Pearce sold 398 shares of the stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total transaction of $48,440.58. Following the completion of the transaction, the insider now owns 11,818 shares of the company’s stock, valued at approximately $1,438,368.78. The disclosure for this sale can be found here. Insiders sold a total of 10,273 shares of company stock valued at $1,217,456 in the last quarter. Insiders own 2.60% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Canada Pension Plan Investment Board purchased a new position in shares of Amedisys in the 3rd quarter valued at about $3,411,000. Martingale Asset Management L P purchased a new position in Amedisys during the 3rd quarter valued at about $2,563,000. Janus Henderson Group PLC increased its holdings in Amedisys by 11.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,745 shares of the health services provider’s stock valued at $593,000 after acquiring an additional 471 shares in the last quarter. AXA purchased a new position in Amedisys during the 3rd quarter valued at about $4,286,000. Finally, Alliancebernstein L.P. increased its holdings in Amedisys by 141.4% during the 3rd quarter. Alliancebernstein L.P. now owns 396,533 shares of the health services provider’s stock valued at $49,551,000 after acquiring an additional 232,255 shares in the last quarter. Institutional investors and hedge funds own 93.58% of the company’s stock.

Shares of AMED stock traded up $1.46 during mid-day trading on Friday, hitting $120.50. The stock had a trading volume of 476,741 shares, compared to its average volume of 654,049. Amedisys has a fifty-two week low of $49.80 and a fifty-two week high of $127.38. The stock has a market capitalization of $3.77 billion, a PE ratio of 54.52, a price-to-earnings-growth ratio of 1.76 and a beta of 1.22. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.06 and a current ratio of 1.06.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Recommended Story: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply